<DOC>
	<DOCNO>NCT00415779</DOCNO>
	<brief_summary>This phase I trial study side effect best dose docetaxel give zoledronic acid patient bone metastasis prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>ZANTE : Zometa Taxotere Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>Docetaxel use alone combination anti-cancer therapy treatment hormone refractory metastatic prostate cancer . Zoledronic acid use treatment bone metastasis prostate cancer . This study combination two agent . The Zante study test dose escalation docetaxel association predetermine dose zoledronic acid ( 2 mg ) , give every 14 day minimum 6 maximum 12 cycle . Sequence A : Docetaxel day 1 zoledronic acid day 2 Sequence B : Zoledronic acid day 1 docetaxel day 2 Patients enrol sequentially cohorts 3 dose level , maximum 36 patient enrol .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written inform consent Hormone refractory prostate cancer Stage IV disease bone metastasis No immunotherapy , hormonal therapy radiotherapy within previous month Performance status &lt; = 2 ( ECOG ) Serum creatinine &lt; 1.5 mg/100ml Serum bilirubin &lt; = 1.25 x UNL ( upper normal limit ) ( &lt; = 1.5 x UNL presence hepatic metastasis ) ; SGOT e SGPT &lt; = 1.5 x UNL ( &lt; = 2.5 x UNL presence hepatic metastasis ) Left ventricular ejection fraction &gt; = 50 % ( measure cardiac ultrasound MUGA scan ) Neutrophils &gt; 1500/mm3 ; platelet &gt; 100000/mm3 ; hemoglobin &gt; 10 g/100 mlÂ· Life expectancy least 3 month Previous malignancy exception radically treat epithelioma Previous chemotherapy Comorbidities would , Investigator 's opinion , contraindicate use drug study Uncontrolled Diabetes Severe cardiac arrhythmia , severe uncontrolled congestive heart failure , severe ischemic cardiac disease myocardial infarction within previous 6 month severe infection cerebral metastasis Preexisting motor sensory neurotoxicity &gt; = grade 2 accord CTC ( Common Toxicity Criteria ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>hormone refractory</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>biphosphonates</keyword>
</DOC>